Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03120936 · ClinicalTrials.gov registry record · Phase 4
The Stay Study: A Demonstration Project Advancing PrEP Delivery in the San Francisco Bay Area Transgender Community
A Phase 4 study of Pre-exposure Prophylaxis and Transgender Persons, sponsored by Public Health Foundation Enterprises.
- Completed
- Registry status
- Phase 4
- Development phase
- 158
- Enrollment target
- 5
- Study locations
NCT03120936: Completed Phase 4 study of Pre-exposure Prophylaxis and Transgender Persons, sponsored by Public Health Foundation Enterprises.
NCT03120936 is a Phase 4 study of Pre-exposure Prophylaxis and Transgender Persons that has completed, run by Public Health Foundation Enterprises. The registered enrollment target is 158 participants, below the 180-participant average among 12 other Pre-exposure Prophylaxis trials with a reported enrollment target (12% lower). The trial reports 5 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03120936, a Phase 4 study of Pre-exposure Prophylaxis and Transgender Persons, has completed, sponsored by Public Health Foundation Enterprises.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 158 participants
- Enrollment target
- 5
- Study locations
Study Summary
The Stay Study is a multi-site, open-label HIV pre-exposure prophylaxis (PrEP) demonstration project for advancing PrEP delivery in the San Francisco Bay Area Transgender Community. Approximately 188 HIV-uninfected participants will be enrolled at 4 sites in San Francisco and Fremont and will be provided Truvada to take orally once daily as PrEP.
Primary Outcome
Combined analysis of PrEP acceptance and refusal rates and sociodemographic correlates of PrEP acceptance and refusal.
Conditions Studied
Interventions
- DRUG Emtricitabine / Tenofovir Disoproxil Oral Tablet
- BEHAVIORAL PrEP support
Study Locations (5)
California
- Tri-City Health Center - Fremont
- Bridge HIV, San Francisco Department of Public Health - San Francisco
- Tom Waddell Urban Health Clinic - San Francisco
- San Francisco Community Health Clinic - San Francisco
- Castro-Mission Health Center - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2017-08-08 |
| Est. Completion | 2020-12-01 |
| Phase | Phase 4 |
What the finished NCT03120936 record still lists
NCT03120936 is an interventional study that assigns participants to a tested intervention. The registered 158 participants enrollment target is mid-sized for trials with a published cap, below the 180-participant average among 12 other Pre-exposure Prophylaxis trials with a reported enrollment target (12% lower).
The record links to 2 conditions, with Pre-exposure Prophylaxis appearing as the primary indexed condition, and to 2 interventions - of which Emtricitabine / Tenofovir Disoproxil Oral Tablet is the first listed.
NCT03120936 lists 5 locations in 1 state (California).
Frequently Asked Questions
What is clinical trial NCT03120936 about?
NCT03120936 is a clinical study titled "The Stay Study: A Demonstration Project Advancing PrEP Delivery in the San Francisco Bay Area Transgender Community". The Stay Study is a multi-site, open-label HIV pre-exposure prophylaxis (PrEP) demonstration project for advancing PrEP delivery in the San Francisco Bay Area Transgender Community. Approximately 188 HIV-uninfected participants will be enrolled at 4 sites in San Francisco and Fremont and will be pro...
What is the current status of trial NCT03120936?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 158 participants. The study started on 2017-08-08. Estimated completion is 2020-12-01.
What conditions does trial NCT03120936 study?
This clinical trial studies the following conditions: Pre-exposure Prophylaxis, Transgender Persons.
What interventions are being tested in trial NCT03120936?
The interventions under investigation include: Emtricitabine / Tenofovir Disoproxil Oral Tablet (DRUG), PrEP support (BEHAVIORAL).
Who is sponsoring clinical trial NCT03120936?
This trial is sponsored by Public Health Foundation Enterprises, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03120936 being conducted?
This trial has 5 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pre-exposure Prophylaxis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03120936's enrollment target sits among peer trials
158 7th of 12 higher than 6 of 12 other Pre-exposure Prophylaxis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pre-exposure Prophylaxis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP Adherence
COMPLETED · Phase 4
-
Hybrid Evaluation of a Home-based HIV Pre-exposure Prophylaxis Program
RECRUITING · NA
-
Stick2PrEP Cisgender Women and Trans Individuals
RECRUITING · NA
-
Predictors of Health Service Utilizations Among Key Population in Washington DC
RECRUITING
-
Gathering Online for Dialogue and Discussion to Enhance Social Support
RECRUITING · NA
-
Case Management Dyad
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04486833 · 158 participants · Phase 1
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
- NCT04697966 · 158 participants · NA
Mechanisms and Predictors of Change in App-Based Mindfulness Training for Adolescents
- NCT04969835 · 158 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
- NCT05230732 · 158 participants · NA
Neuromodulation of Inflammation and Endothelial Function
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI